Michelle Dawson posts

Post published on Twitter/X on 26 Jan 2023 06:44

Back to posts Previous post Next post
Twitter/X Clinical trial clinicaltrials.gov External link integrated into the post Autism terms
Open original post

Information about the link integrated into the post

Clinical trial

Duke University, The Marcus Foundation (2021). Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder. ClinicalTrials.gov. Duke University.

More information

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

Duke University, The Marcus Foundation (2021). Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder. ClinicalTrials.gov. Duke University.

Publication date
24 Feb 2021
Identifier
NCT04294290
Authors
Duke University, The Marcus Foundation
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Duke University
Metadata source
clinicaltrials.gov

Abstract

This is a single site, prospective study of one intravenous infusion of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in toddlers with autism spectrum disorder (ASD). Toddlers 18 to 48 months of age with a confirmed diagnosis of ASD will be eligible to participate. Diagnosis will be confirmed at the time of the eligibility visit at the Duke Center for Autism and Brain Development. All participants will receive a single intravenous dose of 2x106/kg hCT-MSC per kilogram at baseline. Assessments will be conducted at baseline and 6 months, with remote follow-up assessments at 12 months.

Open source